More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$128.63B
EPS
4.52
P/E ratio
12.9
Price to sales
2.46
Dividend yield
4.004%
Beta
0.202074
Previous close
$63.43
Today's open
$64.94
Day's range
$62.82 - $64.94
52 week range
$45.27 - $68.64
CEO
Christopher Boerner
Employees
32500
Headquarters
Princeton, NJ
Exchange
New York Stock Exchange
Shares outstanding
2.04B
Issue type
Common Stock
Healthcare
Pharmaceuticals
Here is What to Know Beyond Why Bristol Myers Squibb Company (BMY) is a Trending Stock
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Zacks Investment Research • 15 hours ago

Bristol Myers Squibb's Growth Portfolio Now Brings In $7.7 Billion a Quarter. Here's Why That Changes the Stock's Story.
Bristol Myers Squibb is a large and well-respected drug maker. The company is facing the normal industry headwind of patent expirations.
The Motley Fool • Nov 14, 2026

Can BMY Sustain Growth in Its Cardiovascular Franchise?
Bristol Myers Squibb is expanding Camzyos??? reach, benefiting from Eliquis?
Zacks Investment Research • Nov 13, 2026

14 dividend stocks selected for long-term growth
There are a variety of ways to select dividend stocks. John Buckingham, a veteran value-oriented stock picker, believes the best approach is to focus on a stock's total return potential, which means emphasizing long-term growth first, and income second.
Market Watch • Nov 13, 2026

Bristol Myers to merge scientific, clinical teams under new R&D structure
Bristol Myers Squibb said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.
Reuters • Nov 12, 2026

Bristol Myers Squibb Announces Evolution of Research & Development Organization
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #Patients--Bristol Myers Squibb Announces Evolution of Research & Development Organization.
Business Wire • Nov 12, 2026

Our Bristol Myers Squibb Stock Pick Is Up 35%. It's Still a Good Bet in Healthcare.
The stock is still attractive trading at 10 times forward earnings.
Barrons • Nov 12, 2026

EXCLUSIVE: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat
The next wave of U.S. drug-price negotiations could put billions of dollars in pharmaceutical revenue under pressure, with Eli Lilly and Co (NYSE:LLY), Gilead Sciences, Inc. (NASDAQ:GILD) facing more immediate exposure and Merck & Co‘s (NYSE:MRK) and Bristol-Myers Squibb Co‘s (NYSE:BMY) confronting a potentially bigger test in the years ahead.
Benzinga • Nov 11, 2026

Will Bristol Myers' Growth Brands Offset Eliquis Headwinds?
Bristol Myers' Growth Portfolio drives 57% of revenues, with key brands gaining traction to offset legacy drug declines and support growth.
Zacks Investment Research • Nov 9, 2026

5 Defensive Dividend Stocks Yielding Up to 8.7% for Retirement Income
Recessions punish shaky payouts, but some companies keep collecting cash anyway. From power lines to pipelines to pill bottles, five low-beta names promise income, yet one of them runs coverage tighter than the rest.
24/7 Wall Street • Nov 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Bristol-Myers Squibb Company commission-free¹. Build wealth for the long term using automated trading and transfers.